timothy sykes logo
TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects Thumbnail
ADD US ONG Google News

TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects

BRYCE TUOHEY•UPDATED MAR. 17, 2026, 5:04 PM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

TG Therapeutics Inc.’s stocks have been trading up by 10.77 percent following promising FDA designations boosting investor confidence.

  • Briumvi demonstrated significant reductions in MS relapse rates, bolstering its competitive positioning against teriflunomide.

  • Revenue guidance for 2026 projects $875M-$900M, largely driven by U.S. sales of Briumvi, aligning close to market expectations.

  • Cash and investment securities position at $199.5M suggests sustainable funding aligned with strategic plans.

Candlestick Chart

Live Update At 17:03:49 EDT: On Tuesday, March 17, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 10.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TG Therapeutics has put forth a promising performance with their multiple sclerosis drug, Briumvi, offering notable clinical trial outcomes that have reinforced market optimism. According to recent data, Briumvi showed impressive durability of effects and safety over a five-year span, corroborated by its low relapse rates. The five-year study findings, published in a notable medical journal, JAMA Neurology, have likely strengthened investor confidence and contributed positively to TGTX shares.

Financially, TG Therapeutics anticipates their 2026 revenue to hover between $875M and $900M, with a majority stemming from Briumvi sales in the U.S. These projections align closely with the consensus, always a comforting signal for stakeholders. Despite some recent earnings misses, the company iterates a position of strength with robust sales growth and strategic expense management.

The company holds a sound cash reserve of nearly $200M, which, coupled with anticipated Briumvi revenues, appears to buffer its operational strategy adequately. Such a cash position serves as a testament to TG Therapeutics’ capacity to sling through their current expansion and product development objectives.

Competitive Edge with Briumvi’s Clinical Data

What sets apart TG Therapeutics is the potential harbored by Briumvi, affirmed by the favorable comparison to competitor drug teriflunomide. Clinical trials revealed that Briumvi significantly lessened relapse rates and MRI activity across its test subjects with highly active relapsing MS. The emerging data highlights Briumvi’s efficacy and fortifies its stance as a competitive player among CD20 therapies. This, combined with new real-world data scheduled for presentation at forthcoming medical conferences, is painting a promising picture.

As clinical milestones stack up till early 2027, the implications of these outcomes might catalyze further stock appreciation. The evaluations suggest heightened efficiency, positioning Briumvi as a top-tier therapy for MS, appealing to healthcare professionals and patients alike over existing alternatives.

More Breaking News

Conclusion

In summary, TG Therapeutics’ strategy and recent data releases underscore a path of calculated growth with Briumvi as a central pillar. The clinical data supports market belief in Briumvi’s competitive edge and potential to command a notable market share in the coming years. Despite financial challenges, TG Therapeutics’ steadfast pursuit of clinical excellence and strategic financial management may well propel it to new heights. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” Traders have much to observe as the firm aligns its strategic vision for 2026 with robust clinical and financial underpinnings.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TGTX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”